Innovative Approaches to Optimal Cancer Care in Canada
Accreditation

As an accredited provider, Dalhousie University, CPD, designates this continuing professional development activity for up to 10.00 credit hours as an accredited group learning Section 1 activity as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Friday – 7.75 credit hrs
Saturday – 2.25 credit hrs

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at: www.ama-assn.org/go/internationalcme.

Educationally co-sponsored by:

[Logo]
Welcome 2
Scientific Program Committee 5
Agenda 6
Speakers 15
Floor Plan 32
Welcome to the inaugural conference on *Innovative Approaches to Optimal Cancer Care in Canada*. On behalf of the Scientific Program Committee, we are excited to present this unique opportunity for Canada’s leaders in cancer control and quality to share insights and best practices from across the country.

Canada is a leader among countries in implementing a robust national cancer control strategy. For more than 10 years, we’ve worked in collaboration with many partners at the provincial and national levels to improve the cancer experience for Canadians. Today, we shine a light on our collective impact and inspire each other to take up innovative practices in our own province or territory.

An extensive roster of international and Canadian thought leaders will take the stage over the next two days and help us delve deeper into our key themes: improving the quality of cancer care, improving the diagnostic process, implementation science and cost and sustainability. We’ll look closely at the issue of implementation and the barriers that so often hamper those efforts. In addition, more than 100 oral, poster and panel presentations will showcase the breadth and depth of Canadian innovations in cancer care.
To ensure these perspectives are grounded in the issues that matter to Canadians living with cancer, we’ve included patient stories and videos throughout the program and a select group of patient advisors from the Canadian Partnership Against Cancer are here to learn and join the conversations.

We’re confident you will be inspired by your colleagues. We hope you take new knowledge home with you as well as new connections to help shape the future of cancer control in Canada.

Thank you for joining us!

Heather Bryant, MD, PhD, CCFP, FRCPC
Vice President, Cancer Control

Geoff Porter MD, FACS, FRCSC
Co-Chair, Scientific Program Committee

Terry Sullivan, PhD
Co-Chair, Scientific Program Committee
Scientific Program Committee

Geoff Porter, Committee Co-Chair
Expert Lead, Clinical Care, Canadian Partnership Against Cancer

Terry Sullivan, Committee Co-Chair
Expert Lead, Quality Initiatives, Canadian Partnership Against Cancer

Heather Bryant
Vice President, Cancer Control, Canadian Partnership Against Cancer

Carole Chambers
Director, Cancer Services, Alberta Health Services Pharmacy

Craig Earle
Program Director, Health Services Research, Ontario Institute for Cancer Research

Christian Finley
Expert Lead, Clinical Measures, Canadian Partnership Against Cancer

Mike Lang
Medical Humanities Researcher, University of Calgary;
Senior Consultant, Alberta Health Services

Michael Milosevic
Director of Research and Quality, Radiation Medicine Program,
Princess Margaret Cancer Centre and University Health Network

Malcolm Moore
President, BC Cancer Agency

Robyn Tamblyn
Scientific Director, Institute of Health Services and Policy Research, Canadian Institutes of Health Research
APRIL 7, 2017

7:00 AM—8:00 AM  Registration/Breakfast

8:00 AM—8:45 AM  Opening remarks and setting the stage
  • Dr. Geoff Porter and Dr. Terry Sullivan, Co-Chairs, Scientific Program Committee
  • Dr. Graham Sher, Chair, Canadian Partnership Against Cancer
  • Dr. Heather Bryant, Vice President, Cancer Control, Canadian Partnership Against Cancer

THEME 1: QUALITY INITIATIVES

Chair: Dr. Geoff Porter, Expert Lead, Clinical Care, Canadian Partnership Against Cancer

In this session, you will:
  > Learn about the principles and challenges of cancer quality improvement initiatives internationally
  > Through examples, gain insights on modality specific approaches to quality improvements in cancer care

8:45 AM—8:55 AM  A Patient Story
  • Mike Lang, Medical Humanities Researcher, University of Calgary; Senior Consultant, Alberta Health Services
  • Use of patient storytelling in cancer

8:55 AM—9:55 AM  International experiences: Principles and challenges of cancer quality improvement initiatives
  • The UK Perspective – Dr. Chris Harrison, National Clinical Director for Cancer, NHS England
  • The US Perspective – Dr. Eric Schneider, Senior Vice President for Policy and Research, The Commonwealth Fund
9:55 AM—10:45 AM  Canadian experiences of quality initiatives

- Canadian Partnership for Quality Radiotherapy – Dr. Michael Milosevic, Director of Research and Quality, Radiation Medicine Program, Princess Margaret Cancer Centre and University Health Network
- Cancer systemic therapy quality initiatives – Dr. Monika Krzyzanowska, Medical Oncologist and Health Services Researcher, Princess Margaret Cancer Centre
- Colorectal cancer quality improvement initiatives - Dr. Marko Simunovic, Professor of Surgery, McMaster University and Juravinski Cancer Centre
- Bladder cancer surgery and quality challenges – Dr. Armen Aprikian, Chief of Urology, McGill University Health Centre
- Panel Discussion and Q&A

10:45 AM—11:00 AM  Break/Poster Viewing

11:00 AM—12:00 PM  Concurrent sessions: CS1 – CS5

CS1: Cost and sustainability (Pier 2)

Chair: Carole Chambers, Director, Cancer Services, Alberta Health Services Pharmacy

- Cost-effectiveness of smoking cessation within an organized CT lung cancer screening program: Implications for clinical intervention opportunities
  - William Evans, McMaster University
- Over 75% of thyroid cancer in Canada is overdiagnosed and over-treated
  - James Dickinson, University of Calgary
- Impacts of American Society Clinical Oncology (ASCO) versus Canadian Task Force on Preventive Health Care (CTFPHC) guidelines for cervical cancer screening
  - Catherine Popadiuk, Memorial University
  - Cindy Gauvreau, Canadian Partnership Against Cancer
- Laparoscopic versus open gastrectomy for gastric cancer patients: A population-based cost analysis
  - Yunni Jeong, University of Toronto
- Are value frameworks useful in helping Canadian cancer systems determine funding for new therapies?
  - Barry D. Stein, Colorectal Cancer Association of Canada
  - Carole Chambers, Alberta Health Services
• What is the value of Cancer Care Ontario’s Breast Cancer Well Follow-up Care Initiative?
  – Nicole Mittmann, Sunnybrook Research Institute

CS2: Implementation science focused on demonstrated improvement in cancer services (Pier 3)
Chair: Meghan McMahon, Project Director, Institute of Health Services and Policy Research, Canadian Institutes of Health Research
• Implementation of a train-the-trainer curriculum to enhance palliative care for children with cancer
  – Kimberley Widger, University of Toronto

• Palliative Radiotherapy Integrated Symptom Management (PRISM): Robust cross-bridging towards patient-centred care
  – Fleur Huang, Cross Cancer Institute

• Improving the quality of cancer care: Pan-Canadian study results on transitions following treatment
  – Susana Huang, Canadian Partnership Against Cancer

• Improving outcomes for cancer patients presenting to Emergency Department (ED) with Febrile Neutropenia
  – Kardi Kennedy, Cancer Centre of Southeastern Ontario
  – Tara Baetz, Cancer Centre of Southeastern Ontario

• The use of administrative data to inform cancer policy initiatives: Integrating administrative data to track the cancer patient’s journey
  – Oliver Bucher, CancerCare Manitoba

• Reduced wait-times to colonoscopy after positive Guaiac Fecal Occult Blood Test (gFOBT) in Ontario’s Diagnostic Assessment Programs (DAPs) compared to usual care
  – Nathaniel Jembere, Cancer Care Ontario
  – Jill Tinmouth, Cancer Care Ontario

CS3: Improving the diagnostic process (Pier 7 & 8)
Chair: Dr. David Mowat, Senior Scientific Leader, Population Health, Canadian Partnership Against Cancer
• Effect of screening test choice on colorectal cancer (CRC) risk and colonoscopy use
  – Andrew J. Coldman, BC Cancer Research Centre

• The breast cancer diagnostic interval across five Canadian provinces: A CanIMPACT study
  – Patti A. Groome, Queen’s University
• Post-colonoscopy colorectal cancers: A step towards identification of root causes and potential points of intervention
  – Clarence K. Wong, University of Alberta

• An analysis of FIT results and neoplastic findings from the Newfoundland and Labrador Colon Cancer Screening Program
  – Jerry S. McGrath, Memorial University of Newfoundland

• Timeliness of referrals using a radiology-initiated notification process for patients suspected of having lung cancer
  – Ashley-Mae Gillson, University of Alberta
  – James Veenstra, Alberta Health Services

• The benefits and harms of breast cancer screening: Time trends for four key indicators
  – Jennifer Payne, Dalhousie University
  – Gregory Doyle, Breast Screening Program for Newfoundland and Labrador

CS4: Specific replicable initiatives on improving quality of cancer care, Part I (Pier 4)
Chair: Dr. Michael Milosevic, Director of Research and Quality, Radiation Medicine Program, Princess Margaret Cancer Centre and University Health Network

• Why does Calgary have one of the lowest hospital death rates for cancer patients in Canada? Perspectives from a large integrated, palliative care program
  – Aynharan Sinnarajah, Alberta Health Services

• Using patient reported outcome measure for personalized cancer care: Impact on patient activation and health care utilization
  – Doris Howell, Princess Margaret Hospital

• Early integration of palliative care in Ontario in cancer settings: INTEGRATE Quality Improvement Project
  – Marnie MacKinnon, Cancer Care Ontario

• Improving screening mammography return rates in overdue women: A recall initiative using signed family physician letters
  – Janette Sam, BC Cancer Agency

• Paramedics Providing Palliative Care at Home Program in Nova Scotia and Prince Edward Island, Canada
  – Marianne Arab, Cancer Care Nova Scotia

• Radiologist one-year recall recommendation rate after a normal breast screen: Implementing provider practice change by performance monitoring and intervention
  – Derek Muradali, Cancer Care Ontario
CSS5: Specific replicable initiatives on improving quality of cancer care, Part II (Pier 5)

Chair: Dr. Deb Dudgeon, Senior Scientific Leader, Person-Centred Perspective, Canadian Partnership Against Cancer

• ‘Swing Rooms’ – an innovative resource utilization model to improve combined care and access to immediate breast reconstruction
  – Esta S. Bovill, University of British Columbia

• Adherence to guidelines for breast cancer survivor care across five Canadian provinces: A CanIMPACT study
  – Mary L. McBride, BC Cancer Agency

• International collaboration in the introduction of transanal total mesorectal excision (TaTME) in a Canadian high volume rectal cancer surgical centre
  – Carl Brown, University of British Columbia

• A pan-Canadian project to rapidly disseminate radiation oncology peer review as a quality improvement initiative: A mixed-method evaluation
  – Michael Brundage, Queen’s University

• Observations on variation in cancer surgery in Canada from prospective data collected at point of care with a synoptic reporting tool
  – Iresha Ratnayake, CancerCare Manitoba
  – Andrea Hilchie-Pye, Cancer Care Nova Scotia
  – Lloyd Mack, Cancer Surgery Alberta

• Radiotherapy (RT) utilization: A knowledge translation program to ensure that all Ontarians who need RT receive it
  – Michael Brundage, Queen’s University

12:00 PM—12:45 PM  Lunch/Poster Viewing

THEME 2: ECONOMICS OF HIGH-QUALITY CARE

Chair: Dr. Terry Sullivan, Expert Lead, Quality Initiatives, Canadian Partnership Against Cancer

In this session, you will:
> Gather insights about promises and limits of tracking real-world evidence of cancer treatment
> Understand clinical and organizational perspectives on cancer cost management, control, purchase, evaluation and gaps
> Learn about Canadian cancer costing initiatives
> Identify and discuss implications of cost on clinical decision-making and potential impact on patient outcomes
12:45 PM—12:55 PM  A Patient Story
- Mike Lang, Medical Humanities Researcher, University of Calgary; Senior Consultant, Alberta Health Services

12:55 PM—2:20 PM  Impact of economics on the cancer system: Perspectives on quality, cost and impact on outcomes
- Using a framework to guide the decision-making process to address Canadian challenges related to cancer treatment demand and expenditure - Dr. Stuart Peacock, Co-Director, Canadian Centre for Applied Research in Cancer Control
- Real-world evidence in cancer chemotherapy from the UK – Dr. Michael Wallington, Senior Public Health Intelligence Analyst, National Cancer Registration and Analysis Service, Public Health England
- The increasing cost of cancer care – Dr. Claire de Oliveira, Expert Lead, Cancer Economics, Canadian Partnership Against Cancer
- Influencing clinical service design by integrating current Canadian costing models – Dr. Tallal Younis, Professor of Medicine and Clinician Investigator, Queen Elizabeth II Health Sciences Centre
- Negotiating, purchasing, evaluating and identifying gaps in cancer drugs - Suzanne McGurn, Assistant Deputy Minister and Executive Officer of Ontario's Public Drug Programs,
- Panel Discussion and Q&A

2:20 PM—2:35 PM  Break/Poster Viewing

THEME 3: IMPROVING THE QUALITY OF CANCER DIAGNOSIS

Chair: Dr. Christian Finley, Expert Lead, Clinical Measures, Canadian Partnership Against Cancer

In this session, you will:
> Reflect on and discuss expanding the role of primary care in cancer diagnosis using the UK as an example
> Review Canadian data to gain insight into the current and future role of primary care in cancer diagnosis
> Learn from Canadian examples of innovations in cancer diagnostic process and reflect on what can be applied in practice

2:35 PM—2:45 PM  A Patient Story
- Mike Lang, Medical Humanities Researcher, University of Calgary; Senior Consultant, Alberta Health Services
2:45 PM—3:55 PM Expanding the role of primary care in cancer control

• The organization of services, including physicians, in cancer diagnosis (Canadian Perspective) – Dr. Eric Wasylenko, Medical Director, Health System Ethics and Policy, Health Quality Council of Alberta
• Pathways, diagnostic testing and role of primary care (International Perspective) – Dr. Greg Rubin, Professor of General Practice and Primary Care, Durham University (UK)
• Primary care in cancer diagnosis (Canadian Perspective) – Dr. Eva Grunfeld, Chair, Chronic Conditions Institute Advisory Board for Canadian Institutes of Health Research
• Panel Discussion and Q&A

3:55 PM—5:05 PM Cancer diagnosis: Quality initiatives and innovations

• Technologies absorbed/integrated in the pathway – Dr. Stirling Bryan, Director, Centre for Clinical Epidemiology & Evaluation
• Canadian pathology quality initiatives and innovations – Dr. John Srigley, Expert Lead, Pathology, Canadian Partnership Against Cancer
• Thoracic oncology program – Nadine Strilchuk, Nurse Practitioner, Thoracic Oncology Program, Alberta Health Services

5:05 PM—5:10 PM Closing remarks: Setting the stage for Day Two

• Dr. Craig Earle, Program Director, Health Services Research, Ontario Institute for Cancer Research

5:10 PM—6:00 PM Reception/Poster Viewing
APRIL 8, 2017

7:30 AM—8:30 AM  Registration/Breakfast

THEME 4: OVERCOMING INERTIA IN THE CANCER SYSTEM: WHY DON’T WE DO WHAT WE KNOW WORKS?

Chair: Dr. Craig Earle, Program Director, Health Services Research, Ontario Institute for Cancer Research

In this session, you will:
> Learn key principles addressing the challenges to implementation of known effective cancer innovations
> Discuss and refine ideas regarding the implementation of specific initiatives that could be done now to improve the quality of cancer care

8:30 AM—9:15 AM  Why we are not applying what we know?
• Dr. David Currow, Chief Cancer Officer, New South Wales

9:15 AM—10:00 AM  Formal reactions
• Dr. Malcolm Moore, President, BC Cancer Agency
• Dr. Mary Gospodarowicz, Medical Director, Princess Margaret Cancer Centre
• Dr. Geoff Porter, Expert Lead, Clinical Care, Canadian Partnership Against Cancer

10:00 AM—10:20 AM  Break/Networking

10:20 AM—11:10 AM  What are five things we could do immediately to improve cancer care in Canada?
• Dr. Craig Earle, Program Director, Health Services Research, Ontario Institute for Cancer Research

Panel & audience discussion
• Dr. Malcolm Moore, President, BC Cancer Agency
• Dr. Ari Meguerditchian, Staff Surgical Oncologist and Health Services Researcher, McGill University
Agenda: Day Two

- Dr. Michael Sherar, President and CEO, Cancer Care Ontario
- Dr. Adalsteinn Brown, Director, Institute of Health Policy, Management and Evaluation, University of Toronto

11:10 AM—11:15 AM  A Patient Story
- Mike Lang, Medical Humanities Researcher, University of Calgary; Senior Consultant, Alberta Health Services

11:15 AM—11:30 AM  What we heard: Now for the future
- Dr. Heather Bryant, Vice President, Cancer Control, Canadian Partnership Against Cancer

11:30 AM—12:30 PM  Formal poster viewing session with poster presenters/
Box lunch

We want your ideas!

Please suggest one or more important things that could be implemented now to improve the quality of cancer care in Canada by the end of Day One.

Text: 647-624-8641

Email: cancerconf@partnershipagainstcancer.ca

Or add your idea to the suggestion box located at the registration desk.
Renowned minds delivering inspiring insights
Graham Sher

Dr. Graham Sher joined the Canadian Partnership Against Cancer's Board of Directors in June 2012 and was elected Chair in 2016. He also served as Chair of the Performance Committee.

Dr. Sher is the Chief Executive Officer of Canadian Blood Services, the agency charged with managing Canada's national blood, plasma and stem cell programs in all provinces and territories across Canada, excluding Quebec, as well as coordinating inter-provincial services for organ and tissue donation and transplantation across the country.

Dr. Sher sits on a number of blood system and health-care related advisory bodies, and has provided consulting support to other countries in the transformation of their blood systems. Dr. Sher is a founding member of the Alliance of Blood Operators and was the first international director on the board of the AABB (formerly the American Association of Blood Banks), serving as its president in 2013-2014. Beyond blood system governance, he is passionate about health system design and management, and is active in a number of areas of health system performance improvement and policy development.

Heather Bryant

Dr. Heather Bryant joined the Canadian Partnership Against Cancer in January 2008, and as Vice President, Cancer Control leads a portfolio of pan-Canadian cancer control programs throughout the cancer continuum, and has led in the development of cancer system performance reporting in Canada.

Dr. Bryant currently chairs the pan-Canadian Lung Cancer Network. She was the inaugural chair of the Institute of Cancer Research's Advisory Board (Canadian Institutes of Health Research) and the National Colorectal Cancer Screening Network. She currently serves as a Board member for BioCanRX, a Canadian Network Centre of Excellence.

Dr. Bryant was elected to the Union for International Cancer Control (UICC) Board of Directors in 2012 and re-elected in 2014. She co-chaired the scientific program committee for UICC's 2012 and 2014 World Cancer Congress. She also chairs the International Cancer Benchmarking Program (Cancer Research UK).

Dr. Bryant studied medicine at the University of Calgary, followed by a fellowship in community medicine and a PhD in epidemiology. She is a Clinical Professor in the departments of Community Health Sciences and Oncology at the University of Calgary. In 2015, she was named one of the 100 Most Powerful Women in Canada by the Women's Executive Network.
Theme 1: Quality initiatives

Geoff Porter
Dr. Geoff Porter is Expert Lead, Clinical Care at the Canadian Partnership Against Cancer. He previously served as the Partnership’s inaugural Senior Scientific Leader, Diagnosis and Clinical Care. Serving in his Partnership role on a part-time basis, Dr. Porter is a Professor of Surgery and the Ramia Chair in Surgical Oncology at Dalhousie University. He also serves as Director of the Cancer Outcomes Research Unit in Halifax.

Dr. Porter studied medicine at Queen’s University in Kingston, Ontario and also holds a Master of Science in medical sciences, specializing in epidemiology, from the University of Alberta. He trained in Surgical Oncology at the MD Anderson Cancer Center in Houston, Texas.

Over the past several years, Dr. Porter has participated in several Partnership initiatives, notably as Clinical Lead for breast cancer surgery in the Synoptic Reporting Tools Project. He acted as Chair of the Electronic Synoptic Surgery Quality Initiative and led the Partnership’s submission for the Choosing Wisely Canada oncology list of recommendations to identify low-value or potentially harmful practices.

Mike Lang
Mike Lang is a specialist with the Person-Centred Care Integration Portfolio of Cancer Control Alberta and a consultant with the Engagement and Patient Experience Department of Alberta Health Services. He is also a documentary filmmaker and medical humanities researcher currently pursuing his PhD at the University of Calgary. His professional and research focus is on using meaningful storytelling to stimulate important conversations in health care.
Chris Harrison

Professor Christopher Harrison is National Clinical Director for Cancer, NHS England, and Medical Director, The Christie NHS Foundation Trust in Manchester.

He qualified in medicine in Manchester in 1983 and after initial training in general practice and then public health, has held a series of senior leadership positions in Manchester and London.

Professor Harrison has a long standing interest in the development of cancer services and improvements in clinical quality. He has been involved in numerous national and international committees related to cancer care, quality of care and standards of clinical practice.

Eric Schneider

Dr. Eric Schneider is senior vice president for policy and research at The Commonwealth Fund, a private foundation that supports independent research on health policy around the globe. Dr. Schneider’s research has focused on evaluating and improving the quality and safety of health care.

Prior to joining the Fund, Dr. Schneider held the RAND Distinguished Chair in Health Care Quality. In 2009, he became the first director of RAND’s Boston office. From 1997 to 2014, he served on the faculty of Harvard Medical School and Harvard School of Public Health where he taught health policy and quality improvement in health care and practiced primary care internal medicine at Brigham and Women’s Hospital in Boston.

Dr. Schneider holds a Bachelor of Science degree, cum laude, in Biology from Columbia University, a Masters of Science degree from the University of California, Berkeley, and an M.D. from the University of California, San Francisco. He is an elected fellow of the American College of Physicians.
Michael Milosevic

Dr. Michael Milosevic is a Clinician Scientist and the Director of Research and Quality, Radiation Medicine Program, Princess Margaret Cancer Centre and University Health Network. He is a Professor in the Department of Radiation Oncology at the University of Toronto, former President of the Canadian Association of Radiation Oncology (CARO) and the Chair of the Canadian Partnership for Quality in Radiotherapy (CPQR).

Dr. Milosevic’s main clinical interest is in the management of gynecologic cancers. His research involves the influence of hypoxia and other aspects of the tumor microenvironment on radiation treatment response, new molecular therapeutics, and the application of adaptive, image-guided external beam radiotherapy and brachytherapy.

Monika Krzyzanowska

Dr. Monika Krzyzanowska is a medical oncologist and health services researcher at the Princess Margaret Cancer Centre in Toronto. She is also the Clinical Lead for Quality Care and Access within the Systemic Treatment Program at Cancer Care Ontario, an Associate Editor at the *Journal of Oncology Practice* and the Chair Elect of the ASCO Quality Care Symposium.

Her research focuses on the science and practice of health care quality as it relates to the delivery of cancer care with special emphasis on the quality of care received by cancer patients on systemic therapy. By combining patient-level intervention studies with population-based research, her work seeks to drive impact at both the institutional and population levels, and close the loop between quality measurement and improvement.

Her research has been supported by the Ontario Institute for Cancer Research, Canadian Institutes of Health Research and the Canadian Breast Cancer Foundation. Dr. Krzyzanowska obtained her medical degree and clinical training in medicine and oncology at the University of Toronto then completed a research fellowship at the Centre for Outcomes and Policy Research at the Dana Farber Cancer Institute.
Dr. Marko Simunovic is a Member of the Departments of Surgery, Oncology, and CEB at McMaster University, and a colorectal surgical oncologist. His research focus on health services research, knowledge translation and quality improvement at the population level. Since 2006, he has been lead investigator on the Quality Improvement in Colorectal Cancer on LHIN4 project – an effort to optimize the surgical care for every LHIN4 patient with colorectal cancer through support interventions for surgeons.

Dr. Armen Aprikian is the Head of the Division of Urology at McGill University and the Chief of Urology at the McGill University Health Centre (MUHC). He graduated from the University of Sherbrooke Medical School and completed his urology residency training at McGill University, where he began his career in prostate and bladder cancer research as a clinical urologic oncologist and was later appointed Assistant Professor of Surgery (Urology). He established the Annual Canadian Senior Resident Urologic Oncology Course which runs to this day.

He is a founding member of Procure, a Quebec-based prostate cancer foundation dedicated to research and public awareness and he initiated a prospective longitudinal comprehensive Biobank project for prostate cancer across the province of Quebec.

His achievements have been recognized through the American Society of Clinical Oncology Young Investigator Award, the American Urologic Association Practising Urologist Award, the Canadian Urology Association Scholarship, the McGill University William Dawson Scholar Career Award and the Quebec FRSQ Senior Clinician Scientist Award.
Dr. Terry Sullivan is Expert Lead for Quality Initiatives with the Partnership, where he has also served as Chair, Quality Initiatives and System Performance since 2011. A behavioural scientist, Dr. Sullivan is a professor and senior fellow at the University of Toronto’s Institute of Health Policy, Management & Evaluation and the Dalla Lana School of Public Health. He is adjunct professor of Oncology at McGill University and Associate Scientist at the Li Ka Shing Knowledge Institute at St. Michael’s Hospital. Among other commitments, Dr. Sullivan chairs the board for the Canadian Agency for Drugs and Technologies in Health and for Public Health Ontario. He is a trustee of the Hospital for Sick Children.

Dr. Sullivan has served in a number of governance and advisory roles in health services and health policy. He was President and CEO of Cancer Care Ontario and founding President of the Institute for Work & Health. Dr. Sullivan has held senior positions in Ontario ministries of Health and Intergovernmental Affairs, and served two Ontario First Ministers through the Premier’s Council on Health Strategy among others.

Dr. Stuart Peacock is a Professor in the Faculty of Health Sciences, Simon Fraser University and Co-Director of the Canadian Centre for Applied Research in Cancer Control (ARCC). ARCC is a pan-Canadian research centre providing interdisciplinary leadership in health economics, services, policy and ethics research. Stuart is also a Distinguished Scientist in Cancer Control Research at the BC Cancer Agency, a member of the Board of Directors of the Canadian Agency for Drugs and Technologies in Health, and past President of the International Society on Priorities in Health Care.

Dr. Peacock has held university positions in Canada, Australia and the UK. Stuart’s main research interests focus on developing more effective cancer services, making health system funding decisions more fair and transparent, and improving the quality of life of cancer patients and survivors. Stuart also holds the Leslie Diamond Chair in Cancer Survivorship.
Michael Wallington

Dr. Michael Wallington works with Public Health England’s National Cancer Registration and Analysis Service as lead analyst for the Systemic Anti-Cancer Therapy (SACT) data set. He has a background in public health, having worked previously in community mental health, disease registration and a collaborative cancer network within the south of England.

Claire de Oliveira

Dr. Claire de Oliveira joined the Canadian Partnership Against Cancer as Expert Lead, Cancer Economics in 2016. In this role, she develops health economics expertise within the Partnership and supports efforts to deepen the capacity to quantify the burden of cancer and assess the economic impact of a coordinated, pan-Canadian approach to cancer control. Dr. de Oliveira is also a member of the Partnership’s Analytic Capacity Building Committee.

Dr. de Oliveira is a health economist at the Centre for Addiction and Mental Health; an assistant professor at the Institute of Health Policy, Management and Evaluation at the University of Toronto; and an adjunct scientist at the Institute for Clinical Evaluative Sciences.

Dr. de Oliveira holds membership with the Canadian Centre for Applied Research in Cancer Control and is one of the program leads for Health Technology Assessment. In addition, she is a collaborator at the Toronto Health Economics Technology Assessment Collaborative.

Dr. de Oliveira holds Masters of Arts and Doctorate degrees in economics from McMaster University. She also holds a licentiate degree in economics from the University of Oporto in Portugal.
**Tallal Younis**

Dr. Tallal Younis is a Professor of Medicine at Dalhousie University and a Clinician Investigator at the Queen Elizabeth II Health Sciences Centre in Halifax, Nova Scotia. His academic practice is focused on breast cancer and he is a co-chair of the provincial multidisciplinary breast site team.

Dr. Younis is a member of the Canadian Partnership Against Cancer’s Diagnosis and Clinical Care Advisory Group and an editor for the medical oncology section of *Current Oncology*. He has also been part of the pan-Canadian Oncology Drug Review Expert Review Committee (pERC) as well as the Partnership’s Research Advisory Group.

Dr. Younis received his medical degree from Cairo University in 1992 and a degree from MRCPUK (Membership of the Royal Colleges of Physicians of the United Kingdom) in 1998. He completed an internal medicine residency in 2001 at Columbia University in New York and a Medical Oncology Fellowship in 2003 at the Roswell Park Cancer Institute in Buffalo. He is board certified (ABIM) in Internal Medicine and Medical Oncology.

**Suzanne McGurn**

Suzanne McGurn is the Assistant Deputy Minister (ADM) and Executive Officer (EO) for the Ontario Public Drug Programs. In this role, she oversees one of the largest drug programs in North America, providing access to prescription medications for nearly four million Ontarians.

Suzanne also plays a significant leadership role within the pan-Canadian Pharmaceutical Alliance (pCPA). Through its efforts, the pCPA is bringing improved value to the publicly funded drug plans across Canada, harnessing the negotiating power of 14 participating jurisdictions with its emphasis on not only affordability, but also greater consistency in access and appropriateness. In addition to the pCPA work, the Ontario Public Drug Programs is an important part of Ontario’s broader efforts to address other key public policy challenges.

She is a graduate of Queen’s University with both a Bachelor of Nursing Sciences and a Masters of Public Administration.
Theme 3: Improving the quality of cancer diagnosis

Christian Finley

Dr. Christian Finley is Expert Lead, Clinical Measures at the Canadian Partnership Against Cancer. In this role he provides content-specific advice and expertise on improving the quality of surgical oncology, as well as using Geographic Information Systems spatial mapping techniques to map system performance in cancer control in Canada.

Dr. Finley is a thoracic surgeon with clinical expertise in lung and esophageal cancer, patient education improvements and regionalization efforts. He practices at St. Joseph’s Healthcare Hamilton and is currently appointed as an Associate Professor in the Department of Surgery (Division of Thoracic Surgery), McMaster University. He is also the Research Chair for the Canadian Association of Thoracic Surgeons.

Dr. Finley has contributed to the Partnerships’ National Initiative for a Synoptic Operative Report in Lung Cancer, Electronic Synoptic Surgical Quality Initiative and led the team that produced a discussion paper on approaches to high-risk, resource intensive cancer surgical care in Canada.

Dr. Finley trained in General Surgery at University of British Columbia and completed his thoracic surgery training at the University of Toronto. He also has a Masters of Public Health from Harvard University.

Eric Waselenko

Dr. Waselenko is a Palliative Care Physician and Clinical Ethicist. He is currently Medical Director, Health System Ethics and Policy, with the Health Quality Council of Alberta. Dr. Waselenko was previously a Physician Consultant in the Pain and Symptom Clinic at Tom Baker Cancer Centre in Calgary, and led the Clinical Ethics Service, assisting with a number of cancer care ethics issues.

Dr. Waselenko serves as Chair of the Ethics Consultative Group for the Public Health Agency of Canada and advises on various committees of the Canadian Association of Provincial Cancer Agencies. His research interests relate to drug funding allocation and biomarkers within the cancer arena, public health and end of life care. He is on the Canadian Medical Association’s Committee on Ethics, and holds academic appointments as Clinical Assistant Professor, Division of Palliative Medicine, Department of Oncology, Cumming School of Medicine, University of Calgary, and as Clinical Lecturer, John Dossetor Health Ethics Centre, and University of Alberta.
Greg Rubin
Dr. Greg Rubin is Professor of General Practice and Primary Care at Durham University, UK and directs their Evaluation, Research and Development Unit.

With over 190 peer-reviewed publications, book chapters and reports, his current research focuses on the diagnosis and management of cancer in primary care and at the interface with secondary care. He leads a substantial program of externally-funded research and service development in this field and is a senior investigator in the Department of Health-funded Policy Research Unit for Cancer Awareness, Screening and Early Diagnosis.

He advises Government and Cancer Research UK on the implementation of cancer strategy, was the Royal College of General Practitioners’ Clinical Lead for Cancer until 2014 and led the first English audit of cancer diagnosis in primary care.

Eva Grunfeld
Dr. Grunfeld is a leader in cancer health services and outcomes research. Her research focuses on evaluation and knowledge translation of cancer health services, covering the entire spectrum of cancer control activities. Knowledge translation is an integral part of all her research activities and she uses a mixed-methods approach including randomized controlled trials, qualitative research and outcomes research.

She conducted several multi-centre RCTs which has influenced clinical practice guidelines and policies internationally in the area of cancer survivorship. Dr. Grunfeld holds many peer-review grants as Principal Investigator and has served on many committees to further the goals of cancer control in Canada and internationally. She obtained her medical degree from McMaster University and doctoral degree in cancer epidemiology from Oxford University.

Dr. Eva Grunfeld is Chair of the Chronic Conditions Institute Advisory Board (IABs) for the Canadian Institutes of Health Research (CIHR). In this role she provides guidance on accelerating the discovery, development, evaluation and integration of solutions that enable Canadians living with chronic conditions to continue to participate actively in society.
Stirling Bryan

Dr. Stirling Bryan is Director of the Centre for Clinical Epidemiology & Evaluation, Vancouver Coastal Health Research Institute and a Professor at UBC’s School of Population & Public Health. Dr. Bryan is a trained economist, specializing in the economics of health care in the UK.

He has a PhD in Economics from Brunel University (UK), and a Masters in Health Economics from the University of York (UK). For many years he led the University of Birmingham team that conducted economic analyses for the UK National Institute for Health & Clinical Excellence (NICE), and later served as a member of the NICE technology appraisals committee. In 2005 he was awarded a Commonwealth Fund Harkness Fellowship and spent a year at Stanford University, researching technology coverage decision making in US health care organizations.

Through his work at UBC and VCH Research Institute, he has continued a focus on policy-relevant research. His current position, sponsored by Vancouver Coastal Health, sees him working alongside policy colleagues in one of BC’s largest regional health authorities.

John Srigley

Dr. John Srigley is Expert Lead, Pathology at the Canadian Partnership Against Cancer. Dr. Srigley is the Chief and Medical Director of the Program of Laboratory Medicine and Genetics at Trillium Health Partners, and a Professor in the Department of Pathology and Molecular Medicine at McMaster University. He also represents Canada on the American Joint Committee on Cancer. In addition to his role as Expert Lead, Pathology, Dr. Srigley is Chair of the National Pathology Standards Committee at the Canadian Partnership Against Cancer.

Dr. Srigley is a graduate of the Faculty of Medicine, University of Toronto, where he also received pathological training, which he continued at MD Anderson Cancer Centre in Houston.

Previously, Dr. Srigley was the inaugural Head of Pathology and Laboratory Medicine Program at Cancer Care Ontario. Dr. Srigley is a Past President of both the International Society of Urological Pathologists and the Ontario Association of Pathologists.

Dr. Srigley was a key leader in completing the Partnership’s National Staging Initiative and securing formal endorsement of the College of American Pathology cancer checklists as pan-Canadian content standards for cancer pathology reporting.
Nadine Strilchuk

Nadine Strilchuk is a Nurse Practitioner for the Thoracic Oncology Program at Alberta Health Services. She is a committee member of the Cancer Care Clinical Strategic Network for Lung Cancer and has been involved in developing innovative processes for expediting lung cancer diagnosis.

Craig Earle

Dr. Craig Earle, Program Director, Health Services Research, Ontario Institute for Cancer Research. Dr. Craig Earle is a Medical Oncologist at Sunnybrook’s Odette Cancer Centre in Toronto, the Director of the Ontario Institute for Cancer Research’s Health Services Research and Clinical Trials Programs, a Senior Scientist and the Cancer Program Leader at the Institute for Clinical Evaluative Sciences, and a Professor of Medicine at the University of Toronto.

Dr. Earle is currently the Chair of the Ontario Steering Committee for Cancer Drug Programs, a member of the pan-Canadian Oncology Drug Review Expert Review Committee, and a Co-Chair of the Ontario Cancer System Quality Index Project Leadership Team.

Dr. Earle’s personal research interests focus on evaluating and improving the quality of care received by patients with advanced cancer and cancer survivors, the effect of financial incentives on care delivery, and making linked, de-identified administrative data more available for health research.
David Currow

Dr. David Currow is the Chief Cancer Officer, NSW and Chief Executive Officer, Cancer Institute NSW, the NSW Government’s cancer control agency. The role of the Cancer Institute NSW is to decrease the incidence of cancer, increase survival for cancer patients and improve the quality of care for people with cancer.

He leads a team of 200 people whose expertise and scope of activities include prevention (tobacco control, ultraviolet light protection), screening (BreastScreen, Cervical Screening and Bowel Screening), service performance and development (including Australia’s sole population-based clinical cancer registry), eviQ – the world’s major evidence-based protocol website in oncology, and Canrefer (linking general practitioners and consumers with multidisciplinary teams), and strategic research and investment.

Prior to joining the Institute in 2010, he was the foundation CEO of Cancer Australia, the Commonwealth’s cancer control agency.

Malcolm Moore

Dr. Malcolm J. Moore is the President of the BC Cancer Agency. Before joining BC Cancer Agency, Dr. Moore was the Daniel E. Bergsagel Professor of Medical Oncology, Head of Medical Oncology and Hematology at the Princess Margaret Cancer Centre in Toronto and a Professor of Medicine and Pharmacology at the University of Toronto. He completed his medical training at the University of Western Ontario and Internal Medicine, Medical Oncology and Clinical Pharmacology training at the University of Toronto.
Theme 4: Overcoming inertia in the cancer system

Mary Gospodarowicz

Dr. Mary Gospodarowicz is Professor of Radiation Oncology at the University of Toronto, Medical Director of the Princess Margaret Cancer Centre at the University Health Network, and Regional Vice President of Cancer Care Ontario. She is the Associate Editor of the Journal of Global Oncology, a Fellow of the American Society in Radiation Oncology (ASTRO), Honorary Fellow of the Royal College of Radiologists in the United Kingdom, and Honorary Fellow of the Faculty of Radiologists in the Royal College of Surgeons of Ireland, and an honorary member of ESTRO, SASRO, and DEGRO.

She holds specialty certifications in internal medicine, medical oncology and radiation oncology.

Her current interests include global cancer control, global access to radiotherapy, and quality cancer care. Dr. Gospodarowicz held leadership positions in the National Cancer Institute of Canada Clinical Trials Group, Canadian Committee on Cancer Staging, and the Canadian Association of Radiation Oncologists, UICC - Union for International Cancer Control. She is a recipient of the ASTRO Gold Medal, American Radium Society Janeway Medal, Warwick Prize from Canadian Cancer Society, and the Order of Canada.

Ari Meguerditchian

Dr. Ari Meguerditchian is a staff surgical oncologist and health services researcher at McGill University. Dr. Meguerditchian completed his medical training at the University of Montreal, where he also received a Master’s degree in Biomedical Sciences. After a General Surgery residency at Laval University, he pursued post-doctoral research and Surgical Oncology fellowships at Roswell Park Cancer Institute in Buffalo, New York, acquiring the skills to deliver evidence-based multidisciplinary cancer care.

During this time, he worked on developing community-wide cancer care quality analysis models, and acquired a better understanding of large administrative and clinical data sources. In collaboration with the National Cancer Database, he helped validate linkage algorithms and developed longitudinal breast cancer treatment tracking tools and quality indicator applications for population-wide knowledge translation analysis.
Theme 4: Overcoming inertia in the cancer system

Michael Sherar
Dr. Michael Sherar is President and CEO of Cancer Care Ontario, a role he was appointed to in 2011. From 2006 to 2011, he was the provincial agency’s Vice-President, Planning and Regional Programs, leading the development of Regional Cancer Programs, including capital planning for cancer services across the province. Dr. Sherar is an Affiliate Scientist at the Techna Institute of the University Health Network where he conducts research and development of minimally invasive thermal therapy technologies for cancer including radiofrequency ablation.

Dr. Sherar holds a BA in Physics from Oxford University and a PhD in Medical Biophysics from University of Toronto.

Adalsteinn D. Brown
Adalsteinn (Steini) Brown is the Director of the Institute for Health Policy, Management and Evaluation and is also the Dalla Lana Chair in Public Health Policy and the Head of the Division of Public Health Policy at the Dalla Lana School of Public Health, University of Toronto. He is a Scientist at the Keenan Research Centre in the Li Ka Shing Knowledge Institute at St. Michael’s Hospital. Past roles include the Assistant Deputy Minister for Strategy and Policy at the Ontario Ministry of Health and Long-term Care and for Science and Research at the Ontario Ministry of Research and Innovation.

He received his undergraduate degree in government from Harvard University and his doctorate from the University of Oxford, where he was a Rhodes Scholar. He has received several leadership awards including being named one of Canada’s “Top 40 Under 40” in recognition for his work on performance measurement in health care. He has held founding roles in consulting, software, and Internet companies and has advised the World Health Organization, banks, software and insurance companies, and health care providers in North America, Europe, and Asia.
The Partnership welcomes five patients as observers to this year’s conference.

As we continue to push our commitment to embed the patient voice across our work, we welcome five of our patient and family advisors to this year’s conference.

**WHO?**
Sponsored advisors:

- Rhonel Biddy (Scarborough)
- Keith Binette (Richmond Hill)
- Sandra Dudych (Winnipeg)
- Robin Harry (Toronto)
- Daniel St. Andrews (Vancouver)

**WHY?**
Advisors will be looking for ways to collaborate on the design and delivery of future events, topics that might interest a lay audience arising from this year’s themes, and ideas to present content that will appeal to a patient audience.

**PLEASE CHAT & CONNECT**
We encourage participants to have conversations with patient advisors (identified by green ribbons) about their cancer experiences, and impressions and questions about the conference. This connection is important to orient advisors to the complexity of health care; and help participants understand what matters to patients as they move across cancer diagnosis to treatment.
CONCURRENT SESSIONS

Concurrent Session 1 (CS1)  
Cost and Sustainability  
Location: Pier 2

Concurrent Session 2 (CS2)  
Implementation Science Focused on Demonstrated Improvement in Cancer Services  
Location: Pier 3

Concurrent Session 3 (CS3)  
Improving the Diagnostic Process  
Location: Pier 7 & 8

Concurrent Session 4 (CS4)  
Specific Replicable Initiatives on Improving Quality of Cancer Care Part I  
Location: Pier 4

Concurrent Session 5 (CS5)  
Specific Replicable Initiatives on Improving Quality of Cancer Care Part II  
Location: Pier 5
Implementation Science
Focused on Demonstrated Improvement in Cancer Services

Cost and Sustainability

Improving the Diagnostic Process

Specific Replicable Initiatives on Improving Quality of Cancer Care
In keeping with CMA Guidelines, program content and selection of speakers are the responsibility of the planning committee. Support is directed toward the costs of the course and not to individual speakers.